<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>isfcppharmaspire</PublisherName>
      <JournalTitle>Pharmaspire</JournalTitle>
      <PISSN>C</PISSN>
      <EISSN>o</EISSN>
      <Volume-Issue/>
      <PartNumber/>
      <IssueTopic>Multidisciplinary</IssueTopic>
      <IssueLanguage>English</IssueLanguage>
      <Season/>
      <SpecialIssue>N</SpecialIssue>
      <SupplementaryIssue>N</SupplementaryIssue>
      <IssueOA>Y</IssueOA>
      <PubDate>
        <Year>-0001</Year>
        <Month>11</Month>
        <Day>30</Day>
      </PubDate>
      <ArticleType>P'Ceutical Chemistry</ArticleType>
      <ArticleTitle>De Novo Designing of Novel Drug-Like Inhibitors of Aldose Reductase</ArticleTitle>
      <SubTitle/>
      <ArticleLanguage>English</ArticleLanguage>
      <ArticleOA>Y</ArticleOA>
      <FirstPage>0</FirstPage>
      <LastPage>0</LastPage>
      <AuthorList>
        <Author>
          <FirstName>Sant Kumar</FirstName>
          <LastName>Verma</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>N</CorrespondingAuthor>
          <ORCID/>
        </Author>
      </AuthorList>
      <DOI/>
      <Abstract>Aldose reductase (AR, ALR2) is a member of aldo-keto reductase (AKR) superfamily. It is the first and rate-limiting enzyme of the polyol pathway. AR plays an essential role in the development of diabetic complications. It is designated as the most legitimate target for managing diabetic complications. One of the key challenges to the successful development of target-specific AR inhibitors is target selectivity. In this research, target-specific drug-like ALR2 inhibitors have been designed using the de novo technique and are present for further synthesis and development.</Abstract>
      <AbstractLanguage>English</AbstractLanguage>
      <Keywords>Aldose Reductase, Diabetic Complications, De novo Designing, Polyol Pathway.</Keywords>
      <URLs>
        <Abstract>https://isfcppharmaspire.com/ubijournal-v1copy/journals/abstract.php?article_id=14959&amp;title=De Novo Designing of Novel Drug-Like Inhibitors of Aldose Reductase</Abstract>
      </URLs>
      <References>
        <ReferencesarticleTitle>References</ReferencesarticleTitle>
        <ReferencesfirstPage>16</ReferencesfirstPage>
        <ReferenceslastPage>19</ReferenceslastPage>
        <References/>
      </References>
    </Journal>
  </Article>
</ArticleSet>